A Systems Approach to Clinical Trial Development with Selection Biomarkers
*Robert Sikorski, Medimmune 


The use of biomarkers to select patients for inclusion in, or exclusion from, clinical trials has garnered much interest. Selection biomarkers can serve as powerful tools to increase the clinical benefit of an investigational agent in defined patient populations. I will discuss a ‘systems’ approach that has served to visualize the landscape of selection biomarkers in active phase III oncology trials. Important patterns in biomarker usage are evident that can guide investigations in both solid and hematological malignancies.